FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy

Home / Alzheimer's / FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy
FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy
June 08, 2021June 8, 2021
0

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, formerly known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With this approval, Aduhelm becomes the first disease-modifying therapy for Alzheimer’s, and the first such therapy to come under FDA review. Disease-modifying therapies are those capable of slowing the progression of a disease itself, and not just its symptoms. It…

You must be logged in to read/download the full post.

The post FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy appeared first on BioNewsFeeds.